Results The most important clinical factor influencing patient outcome was the colorectal cancer itself, and hence there was no significant difference between five year OS (55%), TTP (62%) and PFS (52%). As expected the disease was most likely to recur in patients with more advanced tumours (Duke’s C p = 0.04) and male sex. However, irrespective of the tumour stages Duke’s A-C, the most significant risk factor for tumour recurrence was the presence of anti-CEA CD4+ T cell responses, the majority of which were suppressed by Tregs (p = 0.002). The magnitude of these responses was greater in the group with disease recurrence (p = 0.004). Pre-operative responses to other antigens, including the tumour antigen 5T4, did not reflect outcome.

Conclusion The presence of pre-operative anti-CEA immune responses identifies patients most likely to experience CRC recurrence during the 5 year follow-up period. This relationship holds true irrespective of the tumour stage. This information might be used to direct adjuvant treatment strategies.

Disclosure of Interest None Declared.

PWE-152 SELECTIVE LOSS OF ONCOFOETAL ANTIGEN 5T4-SPECIFIC T CELL RESPONSE CORRELATES WITH PROGRESSION OF COLORECTAL CANCER

doi:10.1136/gutjnl-2013-304907.440

M Scutt, M Davies, S Phillips, H Hargest, A Christian, T Hockey, G Williams, A Gallimore. 1Institute of Infection and Immunity, Cardiff University; 2Department of Surgery, 3Department of Histopathology, Cardiff and Vale University Health Board, Cardiff, UK

Introduction The human oncofoetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues making it an ideal target for cancer immunotherapy. Here, a significant loss of T cell response to 5T4 in patients with more advanced CRC has been identified.

Methods Lymphocyte samples obtained from HLA-typed CRC patients and healthy donor controls were cultured for two weeks with pools of overlapping 20mer 5T4 peptides, spanning the entire protein, before subsequent analysis for antigen specificity, as measured by the highly sensitive IFN-γ/IL-10 ELISPOT assay.

Results Positive 5T4-specific lines were identified in 79% (15/19) of CRC patients and all (11/11) healthy donors tested. Intriguingly, CRC patients respond to significantly fewer candidate epitopes and generate a lower magnitude of IFN-γ responses to 5T4. Furthermore this response diminishes with tumour advancement despite similar responses to the recall antigen PPD. The mechanism of loss of T cell response is independent of HLA-DR type or patient age, but depleted responses to the recall antigen PPD. The mechanism of loss of T cell response diminishes with tumour advancement despite similar responses to the recall antigen PPD. The mechanism of loss of T cell response diminishes with tumour advancement despite similar responses to the recall antigen PPD. The mechanism of loss of T cell response diminishes with tumour advancement despite similar responses to the recall antigen PPD. The mechanism of loss of T cell response diminishes with tumour advancement despite similar responses to the recall antigen PPD.

Conclusion Effective anti-tumour immunotherapy will be reliant upon overcoming such regulation of tumour-specific T cell responses. These data support a rationale for re-stimulating 5T4-specific immune responses in CRC patients, and reducing tumour-induced immunosuppression to enhance immunotherapy.

Disclosure of Interest None Declared.

PWE-154 IRON DEFICIENCY ANAEMIA AS AN INDICATOR OF MALIGNANCY - THE IDIOM STUDY

doi:10.1136/gutjnl-2013-304907.442

A Castro-Silva, T Sheppard, S L Surgeon, E J Williams, J A Snook. 1Gastroenterology Unit, Poole Hospital NHS Foundation Trust, Poole; 2Clinical Research Unit, Bournemouth University, Bournemouth, UK

Introduction Iron deficiency anaemia (IDA) is common. It is of particular importance because about 10% of subjects with IDA over the age of 50 will have an underlying gastro-intestinal (GI) malignancy, often in the absence of other clinical pointers to the diagnosis. IDA is therefore an accepted indication for examination of the GI tract, generally through bidirectional endoscopy. Investigation of IDA is labour-intensive however, and most examinations will not reveal significant pathology. The aim of this study was to determine whether simple and objective clinical variables can identify sub-groups of subjects with IDA who are at clinically useful extremes of risk for underlying malignancy – arbitrarily defined as <1% for low risk and >20% for high risk.

Methods A retrospective study of 720 subjects referred to a single IDA clinic between 2004 and 2012. All had confirmed iron deficiency, minor or no localising symptoms, and subsequent GI tract investigation. Recorded information included age, sex, haemoglobin concentration (Hb), mean cell volume (MCV), iron studies, and final diagnosis.

Results A total of 68 (9.4%) of the study population had a GI malignancy. In the model generated by logistic regression analysis, age (> 70 v < 71), sex (M v F) and Hb quartile were all predictive of the probability of underlying malignancy. The effects of these variables were cumulative.

Percentage of cases of GI malignancy in each subgroup (cases/ number in subgroup):
The prevalence of GI malignancy ranged from 0.0% in younger females with mild anaemia, to over 25% in older males with more severe anaemia. By the pre-defined criteria, the model identified subpopulations of 84 (11% of the total) at extreme low risk, and 117 (16%) at extreme high risk.

**Conclusion** The results confirm previous work identifying age, sex and haemoglobin concentration as variables predictive of underlying malignancy in IDA. Furthermore, the findings suggest that over a quarter of subjects with IDA can be predicted to be of extremely low or high risk on the basis of these simple and objective clinical criteria. This may be of clinical relevance for patient counselling, prioritisation of investigations and allocation of resources. Work is ongoing to validate risk prediction in a prospective study, and to refine the model by inclusion of additional variables.

**Disclosure of Interest** None Declared.

**REFERENCE**


---

**GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMATOLOGY IS NOT A RELIABLE PREDICTOR OF OESOPHAGEAL ADENOCARCINOMA**

doi:10.1136/gutjnl-2013-304907.444

**Introduction** Chronic gastro-oesophageal reflux disease (GORD) is considered a risk factor for development of gastro-oesophageal junction adenocarcinoma. Our aim is to determine the prevalence of GORD symptomatology and Barrett’s columnar metaplasia prior to the diagnosis of distal oesophageal, gastro-oesophageal junction (GOJ) and gastric cardiac adenocarcinomas at GCDD over a 10 year period.

**Methods** A prospective pilot study collected data from patients diagnosed with adenocarcinomas arising from the distal oesophagus, GOJ and cardia in one year. A standardised proforma was designed to capture demographics, clinico-pathological and endoscopic data including the relationship of tumour epicentre with the distal end of the tubular oesophagus, the presence or absence of Barrett’s oesophagus; history of recurrent heartburn or regurgitation.

To avoid reversed causality, we disregarded symptoms that occurred less than five years prior to cancer diagnosis.

**Results** 87 patients were diagnosed with adenocarcinoma of lower oesophagus and cardia between January and December 2011. 73.5% of patients were male and the age at diagnosis ranged between 45 and 97 years. Only 32% of diagnosed cancers were referred through ‘Urgent suspected cancer’ pathway. 43% of patients were smokers and 28% were ex-smokers; 55% drank alcohol regularly. Only 6 out of 37 patients had chronic symptoms (more than 5 years duration) suggestive of reflux including nausea, heartburn and sore tongue. 62% of these patients were on proton pump inhibitors or Histamine blockers at the time of diagnosis. 20% of the endoscopies showed a large hiatus hernia at index endoscopy and 20% showed evidence of Barrett’s (length between 6 and 11cm). Only 30% of patients were treated with curative intervention and the rest were managed by palliative means. 63.8% of diagnosed patients were not alive at one year of follow up out of which one patient had treatment with curative intent.

**Conclusion** This interim report did not reveal a significant correlation between chronic reflux and development of gastrointestinal adenocarcinoma. The number is too small to permit a firm conclusion and we will report further results upon completion of the 10 years.

**Disclosure of Interest** None Declared.

---

**TWO DIMENSIONAL MAPPING OF MUTANT CLONES IN HUMAN COLONIC CRYPTS REVEAL STEM CELL DYNAMICS AND MIGRATION PATTERNS**

doi:10.1136/gutjnl-2013-304907.445

**1** B Careres, **2**M C Baker, **3**P J Tadrous, **4**A Humphries, **4**M Novelli, **5**M Rodriguez-Justo, **5**T A Graham, **6**A McDonald, **N** A Wright. 1*Tumour Biology, Barts Cancer Institute, Barts and The London SMD, QMUL, London; 2Department of Histopathology, Northwick Park Hospital, Harrow, Middlesex; 3Department of Histopathology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; 4Unit of Gastrointestinal Cancer Research, Institute of Cancer Research and Chelsea and Westminster Hospital, London; 5Gwent Centre for Digestive Diseases (GCDD), Royal Gwent Hospital, Newport, UK; 6University of Birmingham, Birmingham, UK.

**Introduction** As new cancer treatments have been introduced, there have been enormous improvements in outcomes for treated patients. They are living longer and the number of survivors of cancer therapy is growing by 3% per year in the UK. 17 000 UK patients are treated annually with pelvic radiotherapy. 80% of patients who receive pelvic radiotherapy are left with chronic alteration in GI function and 50% state that this affects daily activity. There are few data on the nature of the symptoms these patients develop. This interim report did not reveal a significant correlation between chronic reflux and development of gastrointestinal adenocarcinoma. The number is too small to permit a firm conclusion and we will report further results upon completion of the 10 years.

**Disclosure of Interest** None Declared.